Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial

Imagem de Miniatura
Arquivos
art_NOGUEIRA_Omega3_polyunsaturated_fatty_acids_in_treating_nonalcoholic_steatohepatitis_2016.PDF (776.53 KB)
Citações na Scopus
92
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CHURCHILL LIVINGSTONE
Autores
COGLIATI, Bruno
Citação
CLINICAL NUTRITION, v.35, n.3, p.578-586, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: & aims: Few clinical trials have addressed the potential benefits of omega-3 polyunsaturated fatty acids (PUFAs) on non-alcoholic steatohepatitis (NASH). We evaluated the effects of supplementation with omega-3 PUFAs from flaxseed and fish oils in patients with biopsy-proven NASH. Methods: Patients received three capsules daily, each containing 0315 g of omega-3 PUFAs (64% alpha-linolenic [ALA], 16% eicosapentaenoic [EPA], and 21% docosahexaenoic [DHA] acids; n-3 group, n = 27) or mineral oil (placebo group, n = 23). Liver biopsies were evaluated histopathologically by the NASH activity score (NAS). Plasma levels of omega-3 PUFAs were assessed as a marker of intake at baseline and after 6 months of treatment. Secondary endpoints included changes in plasma biochemical markers of lipid metabolism, inflammation, and liver function at baseline and after 3 and 6 months of treatment. Results: At baseline, NAS was comparable between the groups (p = 0.98). After intervention with omega 3 PUFAs, plasma ALA and EPA levels increased (p <= 0.05). However in the placebo group, we also observed increased EPA and DHA (p <= 0.05), suggesting an off-protocol intake of PUFAs. NAS improvement/stabilization was correlated with increased ALA in the n-3 group (p = 0.02) and with increased EPA (p = 0.04) and DHA (p = 0.05) in the placebo group. Triglycerides were reduced after 3 months in the n-3 group compared to baseline (p = 0.01). Conclusions: In NASH patients, the supplementation of omega-3 PUFA from flaxseed and fish oils significantly impacts on plasma lipid profile of patients with NASH. Plasma increase of these PUFAs was associated with better liver histology.
Palavras-chave
Alpha-linolenic acid, Eicosapentaenoic acid, Docosahexaenoic acid, Flaxseed oil, Fish oil, Nonalcoholic steatohepatitis
URI
https://observatorio.fm.usp.br/handle/OPI/14228
Referências
  1. Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
  2. Spadaro L, 2008, DIGEST LIVER DIS, V40, P194, DOI 10.1016/j.dld.2007.10.003
  3. Alwayn IPJ, 2005, TRANSPLANTATION, V79, P606, DOI 10.1097/01.TP.0000150023.86487.44
  4. Dewell A, 2011, J NUTR, V141, P2166, DOI 10.3945/jn.111.142240
  5. Wu HY, 2010, J NUTR, V140, P1937, DOI 10.3945/jn.110.126300
  6. Argo CK, 2015, J HEPATOL, V62, P190, DOI 10.1016/j.jhep.2014.08.036
  7. Araya J, 2004, CLIN SCI, V106, P635, DOI 10.1042/CS20030326
  8. Harper CR, 2006, J NUTR, V136, P83
  9. McClain CJ, 2004, ALCOHOL, V34, P67, DOI 10.1016/j.alcohol.2004.07.007
  10. Janczyk W, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-85
  11. Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012
  12. Scorletti E, 2013, ANNU REV NUTR, V33, P231, DOI 10.1146/annurev-nutr-071812-161230
  13. Parker HM, 2012, J HEPATOL, V56, P944, DOI 10.1016/j.jhep.2011.08.018
  14. LEAN MEJ, 1995, BRIT MED J, V311, P158
  15. Fukumitsu S, 2013, CYTOTECHNOLOGY, V65, P899, DOI 10.1007/s10616-012-9510-x
  16. Torrinhas RSMD, 2013, CLIN NUTR, V32, P503, DOI 10.1016/j.clnu.2012.12.008
  17. Zhu FS, 2008, WORLD J GASTROENTERO, V14, P6395, DOI 10.3748/wjg.14.6395
  18. Iverson SJ, 2001, LIPIDS, V36, P1283, DOI 10.1007/s11745-001-0843-0
  19. Bloedon LT, 2008, J AM COLL NUTR, V27, P65
  20. Capanni M, 2006, ALIMENT PHARM THERAP, V23, P1143, DOI 10.1111/j.1365-2036.2006.02885.x
  21. Nobili V, 2013, NUTR METAB CARDIOVAS, V23, P1066, DOI 10.1016/j.numecd.2012.10.010
  22. Sanyal AJ, 2014, GASTROENTEROLOGY, V147, P377, DOI 10.1053/j.gastro.2014.04.046
  23. Masterton GS, 2010, ALIMENT PHARM THER, V31, P679, DOI 10.1111/j.1365-2036.2010.04230.x
  24. Shirai N, 2005, ANAL BIOCHEM, V343, P48, DOI 10.1016/j.ab.2005.04.037
  25. Zelber-Sagi S, 2011, WORLD J GASTROENTERO, V17, P3377, DOI 10.3748/wjg.v17.i29.3377
  26. Tanaka N, 2008, J CLIN GASTROENTEROL, V42, P413, DOI 10.1097/MCG.0b013e31815591aa
  27. Berlanga Alba, 2014, Clin Exp Gastroenterol, V7, P221, DOI 10.2147/CEG.S62831
  28. Dasarathy S, 2015, J CLIN GASTROENTEROL, V49, P137, DOI 10.1097/MCG.0000000000000099
  29. MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
  30. National Cholesterol Education Program, 2001, NIH PUBL
  31. Pan A, 2007, PLOS ONE, V2, pe1148
  32. Scorletti E, 2014, WELCOME STUDY HEPATO, V60, P1211

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/35
Carregar mais